• July 11, 2020  

    Diffuse Midline Gliomas Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    This outline from the National Cancer Institute provides an overview of diffuse midline gliomas. Diffuse intrinsic pontine gliomas (DIPG), which occur primarily in children, are a subset of diffuse midline gliomas.
  • June 8, 2020  

    New Treatments for Ovarian Cancer in 2020

    Smruti Vidwans, PhD

    Women with ovarian cancer once relied solely on chemotherapy to treat their disease. However, in recent years, treatment options have expanded, and new options are also on the horizon. Read on to learn more about ovarian cancer and how it can be treated. What are the risk factors and symptoms of ovarian cancer? The American Cancer Society estimates that, in 2020, about 21,750 American… Read more »

  • May 30, 2020  

    China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Bookmark

    George Lundberg, MD

    Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

    Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC Bookmark

    George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:

    The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    No OS Boost With Opdivo in Recurrent Glioblastoma Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 25, 2020  

    What’s New in Immunotherapy for Non-Small Cell Lung Cancer?

    Emma Shtivelman, PhD

    Chemotherapy was once the only treatment option for metastatic non-small cell lung cancer (NSCLC). But five years ago, immunotherapy—treatment that boosts a patient’s own immune system to fight cancer—came on the scene. In 2015, the U.S. Food and Drug Administration (FDA) approved the drug nivolumab (brand name Opdivo) as next-line treatment for NSCLC after chemotherapy. Today, new immunotherapy options continue to alter the NSCLC… Read more »

  • May 2, 2020  

    FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer Bookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

    Go to full article published by the FDA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 22, 2020  

    FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 21, 2020  

    5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery Bookmark

    George Lundberg, MD

    Research paper from Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The best chance a patient has for survival with glioblastoma is the extent to which the tumor is initially removed surgically. The tools discussed in this study can help the surgeon maximize extirpation.

    Go to full paper published in Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.